Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer

Restricted access

Bendamustine, a cytotoxic alkylating agent, has shown promising results in solid tumors. An investigator-initiated phase I clinical trial of the anti-vascular endothelial growth factor agent bevacizumab and bendamustine was conducted in patients with advanced cancer, because the 2 drugs have different mechanisms of antitumor activity and nonoverlapping toxicity. Patients were treated with escalating doses of intravenous bendamustine (70, 80, 90, and 100 mg/m2; days 1 and 2) and intravenous bevacizumab (10 mg/kg; days 1 and 15). A conventional “3 + 3” study design was used. Forty-two patients were treated: 23 women and 19 men. The median age was 60 years. Patients had received a median of 4 prior therapies (range, 1-10). The most common cancer types were colorectal (n=9), head and neck (n= 8), non-small cell lung (n=6), and breast (n=5). Overall, 117 cycles were administered (median per patient, 2; range, 1-8). No dose-limiting toxicities were noted during the escalation phase. Therefore, the highest dose (level 4) of bendamustine (100 mg/m2) was used in the expansion phase. The most common toxicities were fatigue (n=22), nausea (n=14), anorexia (n=9), and thrombocytopenia (n=7). Of 38 patients who were evaluable for response, 23 (61%) had stable disease, including 2 (5.2%) who had stable disease for 6 months or more (1 with adenoid cystic carcinoma and 1 with non-small cell lung cancer). This regimen of bendamustine (100 mg/m2) and bevacizumab (10 mg/kg) was well tolerated and yielded disease stabilization in selected heavily pretreated patients with advanced cancer.

Correspondence: Apostolia Maria Tsimberidou, MD, PhD, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: atsimber@mdanderson.org
  • 1.

    BalfourJAGoaKL. Bendamustine. Drugs2001;61:631638; discussion 639-640.

  • 2.

    ChesonBDRummelMJ. Bendamustine: rebirth of an old drug. J Clin Oncol2009;27:14921501.

  • 3.

    BottkeDBatheKWiegelT. Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol2007;183:128132.

    • Search Google Scholar
    • Export Citation
  • 4.

    KosterWHeiderANiederleN. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol2:312316. 2007

    • Search Google Scholar
    • Export Citation
  • 5.

    SchmittelAKnodlerMHortigP. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer2007;55:109113.

    • Search Google Scholar
    • Export Citation
  • 6.

    von MinckwitzGChernozemskyISirakovaL. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs2005;16:871877.

    • Search Google Scholar
    • Export Citation
  • 7.

    ReichmannUBokemeyerCWallwienerD. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol2007;18:19811984.

    • Search Google Scholar
    • Export Citation
  • 8.

    EichbaumMHSchuetzFKhbeisT. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs2007;18:963968.

    • Search Google Scholar
    • Export Citation
  • 9.

    KollmannsbergerCGerlASchleucherN. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs2000;11:535539.

    • Search Google Scholar
    • Export Citation
  • 10.

    RuffertK. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil]. Zentralbl Chir1998;123(Suppl 5):156158.

    • Search Google Scholar
    • Export Citation
  • 11.

    HoffkenKMerkleKSchonfelderM. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol1998;124:627632.

    • Search Google Scholar
    • Export Citation
  • 12.

    CourtneyKDCorcoranRBEngelmanJA. The PI3K pathway as drug target in human cancer. J Clin Oncol2010;28:10751083.

  • 13.

    TherassePArbuckSGEisenhauerEA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000;92:205216.

    • Search Google Scholar
    • Export Citation
  • 14.

    TsimberidouAMFuSNgC. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer2010;116:40864094.

    • Search Google Scholar
    • Export Citation
  • 15.

    SchoffskiPHagedornTGrunwaldV. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. J Cancer Res Clin Oncol2000;126:4147.

    • Search Google Scholar
    • Export Citation
  • 16.

    EisenhauerEATherassePBogaertsJ. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009;45:228247.

    • Search Google Scholar
    • Export Citation
  • 17.

    ReckMHaeringBKoschelG. [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine—a phase II study]. Pneumologie1998;52:570573.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 80 80 7
PDF Downloads 17 17 2
EPUB Downloads 0 0 0